Drug General Information
Drug ID
D01BVI
Former ID
DIB016550
Drug Name
V-101
Drug Type
Small molecular drug
Indication Erythema [ICD9: 695; ICD10:L51-L54] Phase 2 [523141]
Company
Vicept Therapeutics Inc
Structure
Download
2D MOL

3D MOL

Formula
C12H6Cl4S
Canonical SMILES
C1=CC(=CC=C1SC2=CC(=C(C=C2Cl)Cl)Cl)Cl
InChI
1S/C12H6Cl4S/c13-7-1-3-8(4-2-7)17-12-6-10(15)9(14)5-11(12)16/h1-6H
InChIKey
QUWSDLYBOVGOCW-UHFFFAOYSA-N
PubChem Compound ID
PubChem Substance ID
Target and Pathway
Target(s) Alpha-2C adrenergic receptor Target Info Agonist [532145]
KEGG Pathway cGMP-PKG signaling pathway
Neuroactive ligand-receptor interaction
PANTHER Pathway Alpha adrenergic receptor signaling pathway
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Reactome Adrenoceptors
Adrenaline signalling through Alpha-2 adrenergic receptor
Adrenaline,noradrenaline inhibits insulin secretion
G alpha (i) signalling events
G alpha (z) signalling events
Surfactant metabolism
WikiPathways Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Platelet Aggregation (Plug Formation)
Integration of energy metabolism
GPCR ligand binding
GPCR downstream signaling
References
Ref 523141ClinicalTrials.gov (NCT01186068) Dose Response Study of Patients With Erythematous Rosacea. U.S. National Institutes of Health.
Ref 532145Rosacea: update on management and emerging therapies. Skin Therapy Lett. 2012 Dec;17(10):1-4.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.